{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,15]],"date-time":"2026-04-15T20:40:07Z","timestamp":1776285607599,"version":"3.50.1"},"reference-count":29,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2024,5,1]],"date-time":"2024-05-01T00:00:00Z","timestamp":1714521600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,5,1]],"date-time":"2024-05-01T00:00:00Z","timestamp":1714521600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,5,1]],"date-time":"2024-05-01T00:00:00Z","timestamp":1714521600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2024,5,1]],"date-time":"2024-05-01T00:00:00Z","timestamp":1714521600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2024,5,1]],"date-time":"2024-05-01T00:00:00Z","timestamp":1714521600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2024,5,1]],"date-time":"2024-05-01T00:00:00Z","timestamp":1714521600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2024,5,1]],"date-time":"2024-05-01T00:00:00Z","timestamp":1714521600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.fr","clinicalkey.jp","msard-journal.com","clinicalkey.es","clinicalkey.com.au","clinicalkey.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Multiple Sclerosis and Related Disorders"],"published-print":{"date-parts":[[2024,5]]},"DOI":"10.1016\/j.msard.2024.105518","type":"journal-article","created":{"date-parts":[[2024,2,28]],"date-time":"2024-02-28T10:06:45Z","timestamp":1709114805000},"page":"105518","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":7,"special_numbering":"C","title":["Isolated myelin oligodendrocyte glycoprotein antibody-associated optic neuritis in adults: The importance of age of onset and prognosis-related radiological features"],"prefix":"10.1016","volume":"85","author":[{"given":"Juan","family":"Zhao","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xiaoli","family":"Chen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jingxiao","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lei","family":"Liu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jiawei","family":"Wang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Liping","family":"Zhu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"4","key":"10.1016\/j.msard.2024.105518_bib0001","doi-asserted-by":"crossref","first-page":"446","DOI":"10.1136\/jnnp-2014-310206","article-title":"MRI and retinal abnormalities in isolated optic neuritis with myelin oligodendrocyte glycoprotein and aquaporin-4 antibodies: a comparative study","volume":"87","author":"Akaishi","year":"2016","journal-title":"J. Neurol. Neurosurg. Psychiatry."},{"issue":"12","key":"10.1016\/j.msard.2024.105518_bib0002","doi-asserted-by":"crossref","first-page":"1639","DOI":"10.1016\/j.ophtha.2019.07.004","article-title":"Anti-myelin oligodendrocyte glycoprotein optic neuritis presenting with dense premacular hemorrhage","volume":"126","author":"Budoff","year":"2019","journal-title":"Ophthalmology"},{"key":"10.1016\/j.msard.2024.105518_bib0003","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1016\/j.ajo.2018.07.020","article-title":"Myelin oligodendrocyte glycoprotein antibody-positive optic neuritis: clinical characteristics, radiologic clues, and outcome","volume":"195","author":"Chen","year":"2018","journal-title":"Am. J. Ophthalmol."},{"key":"10.1016\/j.msard.2024.105518_bib0004","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1016\/j.jneuroim.2018.05.014","article-title":"Different features between pediatric-onset and adult-onset patients who are seropositive for MOG-IgG: a multicenter study in South China","volume":"321","author":"Chen","year":"2018","journal-title":"J. Neuroimmunol."},{"key":"10.1016\/j.msard.2024.105518_bib0005","doi-asserted-by":"crossref","DOI":"10.1016\/j.msard.2020.102399","article-title":"Clinical and laboratory features distinguishing MOG antibody disease from multiple sclerosis and AQP4 antibody-positive neuromyelitis optica","volume":"45","author":"Ciotti","year":"2020","journal-title":"Mult. Scler. Relat. Disord."},{"key":"10.1016\/j.msard.2024.105518_bib0006","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1016\/bs.irn.2022.06.011","article-title":"Sex and gender differences in autoimmune demyelinating CNS disorders: multiple sclerosis (MS), neuromyelitis optica spectrum disorder (NMOSD) and myelin-oligodendrocyte-glycoprotein antibody associated disorder (MOGAD)","volume":"164","author":"Diem","year":"2022","journal-title":"Int. Rev. Neurobiol."},{"issue":"8","key":"10.1016\/j.msard.2024.105518_bib0007","doi-asserted-by":"crossref","first-page":"909","DOI":"10.1136\/jnnp-2012-304695","article-title":"Cerebrospinal fluid oligoclonal bands in multiple sclerosis and clinically isolated syndromes: a meta-analysis of prevalence, prognosis and effect of latitude","volume":"84","author":"Dobson","year":"2013","journal-title":"J. Neurol. Neurosurg. Psychiatry."},{"issue":"2","key":"10.1016\/j.msard.2024.105518_bib0008","article-title":"Frequency of myelin oligodendrocyte glycoprotein antibodies in a large cohort of neurological patients","volume":"7","author":"Held","year":"2021","journal-title":"Mult. Scler. J. Exp. Transl. Clin."},{"issue":"7","key":"10.1016\/j.msard.2024.105518_bib0009","doi-asserted-by":"crossref","first-page":"941","DOI":"10.1177\/1352458512466317","article-title":"Acute disseminated encephalomyelitis followed by recurrent or monophasic optic neuritis in pediatric patients","volume":"19","author":"Huppke","year":"2013","journal-title":"Mult. Scler."},{"issue":"1","key":"10.1016\/j.msard.2024.105518_bib0010","doi-asserted-by":"crossref","first-page":"261","DOI":"10.1186\/s12974-020-01824-2","article-title":"in cooperation with the Neuromyelitis Optica Study adults (NEMOS), 2021. Cerebrospinal fluid findings in patients with myelin oligodendrocyte glycoprotein (MOG) antibodies. Part 1: results from 163 lumbar punctures in 100 adult patients","volume":"17","author":"Jarius","year":"2021","journal-title":"J. Neuroinflamm."},{"issue":"1","key":"10.1016\/j.msard.2024.105518_bib0011","doi-asserted-by":"crossref","first-page":"280","DOI":"10.1186\/s12974-016-0718-0","article-title":"MOG-IgG in NMO and related disorders: a multicenter study of 50 patients. Part 2: epidemiology, clinical presentation, radiological and laboratory features,treatment responses, and long-term outcome","volume":"13","author":"Jarius","year":"2016","journal-title":"J. Neuroinflamm."},{"issue":"6","key":"10.1016\/j.msard.2024.105518_bib0012","doi-asserted-by":"crossref","first-page":"e163","DOI":"10.1212\/NXI.0000000000000163","article-title":"Antibodies to MOG in adults with inflammatory demyelinating disease of the CNS","volume":"2","author":"Kim","year":"2015","journal-title":"Neurol. Neuroimmunol. Neuroinflamm."},{"issue":"3","key":"10.1016\/j.msard.2024.105518_bib0013","doi-asserted-by":"crossref","first-page":"276","DOI":"10.1001\/jamaneurol.2013.5857","article-title":"Neuromyelitis optica spectrum disorders with aquaporin-4 and myelin-oligodendrocyte glycoprotein antibodies: a comparative study","volume":"71","author":"Kitley","year":"2014","journal-title":"JAMa Neurol"},{"issue":"1","key":"10.1016\/j.msard.2024.105518_bib0014","doi-asserted-by":"crossref","first-page":"302","DOI":"10.1186\/s12974-018-1335-x","article-title":"Chronic relapsing inflammatory optic neuropathy (CRION): a manifestation of myelin oligodendrocyte glycoprotein antibodies","volume":"15","author":"Lee","year":"2018","journal-title":"J. Neuroinflamm."},{"issue":"7","key":"10.1016\/j.msard.2024.105518_bib0015","doi-asserted-by":"crossref","first-page":"e1316","DOI":"10.1002\/cti2.1316","article-title":"Pathogenesis of autoimmune demyelination: from multiple sclerosis to neuromyelitis optica spectrum disorders and myelin oligodendrocyte glycoprotein antibody-associated disease","volume":"10","author":"Lopez","year":"2021","journal-title":"Clin. Transl. Immunol."},{"issue":"3","key":"10.1016\/j.msard.2024.105518_bib0016","doi-asserted-by":"crossref","first-page":"305","DOI":"10.1097\/ICB.0000000000000977","article-title":"Venous stasis retinopathy secondary to myelin oligodendrocyte glycoprotein antibody-positive optic neuritis","volume":"16","author":"Lukewich","year":"2022","journal-title":"Retin. Cases. Brief. Rep."},{"issue":"1","key":"10.1016\/j.msard.2024.105518_bib0017","doi-asserted-by":"crossref","first-page":"83","DOI":"10.5935\/0004-2749.20230012","article-title":"Myelin oligodendrocyte glycoprotein antibody-associated optic neuritis: an update","volume":"86","author":"Messias","year":"2023","journal-title":"Arq. Bras. Oftalmol."},{"issue":"1","key":"10.1016\/j.msard.2024.105518_bib0018","doi-asserted-by":"crossref","first-page":"e48","DOI":"10.1097\/WNO.0000000000000945","article-title":"Sj\u00f6gren disease and myelin oligodendrocyte glycoprotein antibody-associated optic neuritis","volume":"41","author":"Mittal","year":"2021","journal-title":"J. Neuroophthalmol."},{"issue":"4","key":"10.1016\/j.msard.2024.105518_bib0019","doi-asserted-by":"crossref","first-page":"307","DOI":"10.1016\/j.autrev.2015.12.004","article-title":"Anti-MOG antibody: the history, clinical phenotype, and pathogenicity of a serum biomarker for demyelination","volume":"15","author":"Ramanathan","year":"2016","journal-title":"Autoimmun. Rev."},{"issue":"6","key":"10.1016\/j.msard.2024.105518_bib0020","doi-asserted-by":"crossref","first-page":"752","DOI":"10.1001\/archneurol.2011.2956","article-title":"Anti-myelin oligodendrocyte glycoprotein antibodies in pediatric patients with optic neuritis","volume":"69","author":"Rostasy","year":"2012","journal-title":"Arch. Neurol."},{"issue":"6","key":"10.1016\/j.msard.2024.105518_bib0021","doi-asserted-by":"crossref","first-page":"474","DOI":"10.1212\/WNL.0000000000000101","article-title":"Distinction between MOG antibody-positive and AQP4 antibody-positive NMO spectrum disorders","volume":"82","author":"Sato","year":"2014","journal-title":"Neurology"},{"key":"10.1016\/j.msard.2024.105518_bib0022","doi-asserted-by":"crossref","DOI":"10.1016\/j.msard.2020.102638","article-title":"Variability of cerebrospinal fluid findings by attack phenotype in myelin oligodendrocyte glycoprotein-IgG-associated disorder","volume":"47","author":"Sechi","year":"2021","journal-title":"Mult. Scler. Relat. Disord."},{"issue":"6","key":"10.1016\/j.msard.2024.105518_bib0023","doi-asserted-by":"crossref","first-page":"741","DOI":"10.1001\/jamaneurol.2021.0912","article-title":"Positive predictive value of myelin oligodendrocyte glycoprotein autoantibody testing","volume":"78","author":"Sechi","year":"2021","journal-title":"JAMa Neurol"},{"key":"10.1016\/j.msard.2024.105518_bib0024","doi-asserted-by":"crossref","DOI":"10.3389\/fneur.2022.885218","article-title":"Myelin Oligodendrocyte Glycoprotein Antibody-Associated Disease (MOGAD): a review of clinical and MRI features, diagnosis, and management","volume":"13","author":"Sechi","year":"2022","journal-title":"Front. Neurol."},{"key":"10.1016\/j.msard.2024.105518_bib0025","doi-asserted-by":"crossref","DOI":"10.3389\/fneur.2021.673339","article-title":"Antibody-mediated autoimmune diseases of the CNS: challenges and approaches to diagnosis and management","volume":"12","author":"Sechi","year":"2021","journal-title":"Front. Neurol."},{"key":"10.1016\/j.msard.2024.105518_bib0026","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1016\/j.jns.2019.03.014","article-title":"Clinical characteristics and outcomes of myelin oligodendrocyte glycoprotein antibody-seropositive optic neuritis in varying age groups: a cohort study in China","volume":"400","author":"Song","year":"2019","journal-title":"J. Neurol. Sci."},{"issue":"4","key":"10.1016\/j.msard.2024.105518_bib0027","doi-asserted-by":"crossref","first-page":"e572","DOI":"10.1212\/NXI.0000000000000572","article-title":"Does time equal vision in the acute treatment of a cohort of AQP4 and MOG optic neuritis?","volume":"6","author":"Stiebel-Kalish","year":"2019","journal-title":"Neurol. Neuroimmunol. Neuroinflamm."},{"issue":"1","key":"10.1016\/j.msard.2024.105518_bib0028","doi-asserted-by":"crossref","first-page":"149","DOI":"10.1177\/13524585211011450","article-title":"Optic chiasm involvement in AQP-4 antibody-positive NMO and MOG antibody-associated disorder","volume":"28","author":"Tajfirouz","year":"2022","journal-title":"Mult. Scler."},{"issue":"4","key":"10.1016\/j.msard.2024.105518_bib0029","doi-asserted-by":"crossref","first-page":"1128","DOI":"10.1111\/ene.15239","article-title":"Late onset neuromyelitis optica spectrum disorder with anti-aquaporin 4 and anti-myelin oligodendrocyte glycoprotein antibodies","volume":"29","author":"Wang","year":"2022","journal-title":"Eur. J. Neurol."}],"container-title":["Multiple Sclerosis and Related Disorders"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S221103482400097X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S221103482400097X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,1,28]],"date-time":"2025-01-28T10:59:41Z","timestamp":1738061981000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S221103482400097X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,5]]},"references-count":29,"alternative-id":["S221103482400097X"],"URL":"https:\/\/doi.org\/10.1016\/j.msard.2024.105518","relation":{},"ISSN":["2211-0348"],"issn-type":[{"value":"2211-0348","type":"print"}],"subject":[],"published":{"date-parts":[[2024,5]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Isolated myelin oligodendrocyte glycoprotein antibody-associated optic neuritis in adults: The importance of age of onset and prognosis-related radiological features","name":"articletitle","label":"Article Title"},{"value":"Multiple Sclerosis and Related Disorders","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.msard.2024.105518","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}],"article-number":"105518"}}